A Multicenter, Single-Arm, Phase II Trial of RC48-ADC Combined with Radiotherapy, PD-1/PD-L1 Inhibitor Sequential GM-CSF and IL-2 (PRaG3.0 regimen) for the Treatment of HER2-Expressing Advanced Solid Tumors

被引：0
|
作者：
Xu, M. [1 ]
Kong, Y. [1 ]
Xing, P. [1 ]
Chen, R. [2 ]
Ma, Y. [1 ]
Shan, C. [2 ]
LiYuan, Z. [3 ]
机构：
[1] Second Affiliated Hosp Soochow Univ, Dept Radiotherapy & Oncol, Suzhou, Peoples R China
[2] Second Affiliated Hosp Soochow Univ, Suzhou, Peoples R China
[3] Soochow Univ, Inst Radiotherapy & Oncol, Suzhou, Peoples R China
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2022年 / 114卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2957
引用
收藏
页码：E428 / E428
页数：1
相关论文
共 25 条
  • [1] A multicenter, phase II trial of RC48-ADC combined with radiotherapy, PD-1/PD-L1 inhibitor, GM-CSF, and sequential IL-2 (PRaG3.0 regimen) for salvage therapy in patients with HER2-expressing advanced solid tumors
    Xu, Meiling
    Chen, Rongzheng
    Xing, Pengfei
    Kong, Yuehong
    Zhao, Xiangrong
    Zhang, Junjun
    Cai, Shang
    Zhang, Liyuan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] An open-label, multicenter, phase II study of RC48-ADC combined with radiotherapy, PD-1/PD-L1 inhibitor sequential GM-CSF and IL-2 for salvage therapy in patients with HER2-expressing advanced solid tumors(PRaG3.0).
    Xu, Meiling
    Kong, Yuehong
    Xing, Pengfei
    Chen, Rongzheng
    Ma, Yifu
    Shan, Chanchan
    Zhang, Liyuan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [3] PD-1 inhibitors combined with radiotherapy and GM-CSF, sequentially followed by IL-2 (PRaG 2.0) regimen in advanced refractory solid tumors: A prospective, multicenter, single-arm clinical trial
    Xing, Pengfei
    Yang, Jiabao
    Xu, Meiling
    Wang, Jian
    Han, Dali
    Kong, Yuehong
    Zhang, Junjun
    Zhang, Liyuan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] PD-1 Inhibitor Combined with Hypofractionated Radiotherapy and GM-CSF with or without IL-2 (PRaG Regimens) Rechallenge for Acquiring Resistance to PD-1/ PD-L1 Inhibitor in Advanced Solid Tumors
    Xu, M.
    Xing, P.
    Kong, Y.
    Zhang, C.
    Zhao, X.
    Zhang, J.
    Zhang, L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E427 - E428
  • [5] PD-1 Inhibitors Combined with Radiotherapy and GM-CSF, Sequentially Followed by IL-2 (PRaG 2.0) Regimen in Metastatic Tumors: A Prospective, Multicenter, Single-Arm Clinical Trial
    Xing, P.
    Yang, J.
    Xu, M.
    Kong, Y.
    Wang, J.
    Wang, J.
    Han, D.
    Zhang, L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E427 - E427
  • [6] PRaG regimens (PD-1 inhibitor combined with radiotherapy and GM-CSF with or not IL-2) rechallenge for patients with acquiring resistance to PD-1/PD-L1 inhibitors in refractory advanced solid tumors
    Xu, Meiling
    Xing, Pengfei
    Kong, Yuehong
    Zhang, Chenyang
    Zhao, Xiangrong
    Zhang, Junjun
    Zhang, Liyuan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [7] A phase II trial of PD-1 inhibitor combined with Radiotherapy and GM-CSF (PRaG) in metastatic tumors
    Zhang, L.
    Kong, Y.
    Xing, P.
    Zhao, X.
    Chen, G.
    Ma, Y.
    Zou, L.
    Peng, Q.
    Xu, M.
    Xu, Z.
    RADIOTHERAPY AND ONCOLOGY, 2021, 161 : S492 - S492
  • [8] A prospective, multicenter, single-arm clinical trial of PD-1 inhibitors in combination with radiotherapy and GM-CSF, sequentially followed by IL-2 (PRaG 2.0) therapy in advanced refractory solid tumors
    Xing, Pengfei
    Yang, Jiabao
    Kong, Yuehong
    Xu, Meiling
    Wang, Jian
    Wang, Jianshe
    Ma, Yifu
    Zhang, Liyuan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [9] A Prospective Clinical Trial of Radiotherapy Combined with PD-1 Inhibitors and GM-CSF, Sequentially Followed by IL-2 (PRaG 2.0) Regimen in Advanced Refractory Solid Tumors
    Xing, P.
    Yang, J., Sr.
    Xu, M.
    Kong, Y.
    Zhang, J.
    Zhao, X.
    Zhang, L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : E157 - E158
  • [10] PD-1 Inhibitor Combined with Radiotherapy and GM-CSF with or not IL-2 (PRaG regimen) in Patients with Microsatellite Stable Metastatic Colorectal Cancer
    Yang, J.
    Xing, P.
    Kong, Y.
    Xu, M.
    Zhang, L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E154 - E154
123